Success Metrics

Clinical Success Rate
83.3%

Based on 5 completed trials

Completion Rate
83%(5/6)
Active Trials
5(45%)
Results Posted
60%(3 trials)
Terminated
1(9%)

Phase Distribution

Ph phase_2
4
36%
Ph phase_1
7
64%

Phase Distribution

7

Early Stage

4

Mid Stage

0

Late Stage

Phase Distribution11 total trials
Phase 1Safety & dosage
7(63.6%)
Phase 2Efficacy & side effects
4(36.4%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

83.3%

5 of 6 finished

Non-Completion Rate

16.7%

1 ended early

Currently Active

5

trials recruiting

Total Trials

11

all time

Status Distribution
Active(5)
Completed(5)
Terminated(1)

Detailed Status

Recruiting5
Completed5
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
5
Success Rate
83.3%
Most Advanced
Phase 2

Trials by Phase

Phase 17 (63.6%)
Phase 24 (36.4%)

Trials by Status

terminated19%
recruiting545%
completed545%

Recent Activity

5 active trials
Showing 5 of 11
recruitingphase_1

Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

NCT07287917
recruitingphase_2

Pediatric Precision Laboratory Advanced Neuroblastoma Therapy

NCT02559778
recruitingphase_2

TArgeting Type 1 Diabetes Using POLyamines (TADPOL)

NCT05594563
recruitingphase_2

Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer

NCT06059118
recruitingphase_1

DFMO Maintenance for Patients With Relapsed/Refractory Ewing Sarcoma or Osteosarcoma

NCT06892678
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT07287917Phase 1

Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

Recruiting
NCT02559778Phase 2

Pediatric Precision Laboratory Advanced Neuroblastoma Therapy

Recruiting
NCT05594563Phase 2

TArgeting Type 1 Diabetes Using POLyamines (TADPOL)

Recruiting
NCT06059118Phase 2

Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer

Recruiting
NCT06892678Phase 1

DFMO Maintenance for Patients With Relapsed/Refractory Ewing Sarcoma or Osteosarcoma

Recruiting
NCT02030964Phase 1

N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan

Completed
NCT05500508Phase 1

Oral AMXT 1501 Dicaprate in Combination With IV DFMO

Terminated
NCT02395666Phase 2

Preventative Trial of Difluoromethylornithine (DFMO) in High Risk Patients With Neuroblastoma That is in Remission

Completed
NCT02139397Phase 1

Study of Difluoromethylornithine (DFMO) in Combination With Bortezomib for Relapsed or Refractory Neuroblastoma

Completed
NCT01059071Phase 1

Safety Study for Refractory or Relapsed Neuroblastoma With DFMO Alone and in Combination With Etoposide

Completed
NCT03536728Phase 1

Oral AMXT 1501 Dicaprate in Combination With DFMO

Completed

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11